

Susceptibility of clinical *Candida* species isolates to antifungal agents by E-test, Southern Iran: A five year study

Badiee P*, Alborzi A

Prof. Alborzi Microbiology Research Center, Mycology Department, Shiraz University of Medical Sciences, Shiraz, Iran.

Received: September 2011, Accepted: November 2011.

ABSTRACT

Background and Objectives: The incidence of fungal infections in immunocompromised patients, especially by *Candida* species, has increased in recent years. This study was designed to identify *Candida* species and determine antifungal susceptibility patterns of 595 yeast strains isolated from various clinical specimens.

Material and Methods: Identification of the isolates were determined by the API 20 C AUX kit and antifungal susceptibilities of the species to fluconazole, amphotericin B, ketoconazole, itraconazole, voriconazole, and caspofungin were determined by the agar-based E-test method.

Results: *Candida albicans* (48%) was the most frequently isolated species, followed by *Candida kruzei* (16.1%), *Candida glabrata* (13.5%), *Candida kefyr* (7.4%), *Candida parapsilosis* (4.8%), *Candida tropicalis* (1.7%) and other species (8.5%). Resistance varies depending on the species and the respective antifungal agents. Comparing the MIC₉₀ for all the strains, the lower MIC₉₀ was observed for caspofungin (0.5 µg/ml). The MIC₉₀ for all *Candida* species were 64 µg/ml for fluconazole, 0.75 µg/ml for amphotericin B, 4 µg/ml for ketoconazole, 4 µg/ml for itraconazole, and 2 µg/ml for voriconazole.

Conclusions: Species definition and determination of antifungal susceptibility patterns are advised for the proper management and treatment of patients at risk for systemic candidiasis. Resistance to antifungal agents is an alarming sign for the emerging common nosocomial fungal infections.

Keywords: *Candida*, amphotericin B, itraconazole, voriconazole, antifungal susceptibility, E - test

INTRODUCTION

Systemic candidiasis (SC) is the most common invasive fungal infection as the nosocomial infection in patients undergoing major surgeries during prolonged neutropenia, transplantation and extended hospital stays of days to weeks, (1). This infection is potentially a life-threatening complication in immunocompromised patients. The introduction of novel antineoplastic agents, antifungals, antibacterial

and antivirals over the past 10 years has led to a shift in fungal epidemiology (2, 3) and fever without specific signs and symptoms of localized fungal infection is the most common clinical presentation. Intensive and long-term use of antifungals leads to a decline in sensitivity and resistance development of *Candida* strains (4). Antifungal resistance surveillance serves as a major strategy for prophylaxis, empirical therapy, and treatment of SC. For the management of patients suffering from SC, determination of the changes in the distribution of *Candida* species and respective sensitivity pattern to antifungal agents are important.

Antifungal prophylaxis is warranted in patients with developing risk of SC. As definitive early diagnosis is difficult, empiric therapy of antifungal agents has become a standard of practice in immune-suppressed patients like neutropenic patients who had received

* Corresponding author: Parisa Badiee PhD
Address: Prof. Alborzi Clinical Microbiology Research Center, Nemazi Hospital, Zand Ave, Shiraz, Iran.
Tel: +98-711-6474292
Fax: +98-711-6474303
E-mail: Badieep@gmail.com

Table 1. Distributions of *Candida* species isolates from patients 2005-2009.

Species	No. of isolates	% of isolates
<i>Candida albicans</i>	285	48%
<i>Candida krusei</i>	96	16.1%
<i>Candida glabrata</i>	80	13.5%
<i>Candida kefyr</i>	44	7.4%
<i>Candida parapsilosis</i>	29	4.8%
<i>Candida tropicalis</i>	10	1.7%
Others*	51	8.5%
Total	595	100

*Others include *C. dublinensis* 9, *C. apicola* 8, *C. famata* 4, *C. zeylanoides* 6, *Cryptococcus neoformans* 9, *Trichosporon beigelii*. 8, *Saccharomyces cerevicea* 7.

broad spectrum antibacterial therapy but remain persistently febrile. The antifungal susceptibility testing of pathogenic fungi can manage the selection of adequate therapy and also provide an estimate of antifungal efficacy. Monitoring of drug resistance development can predict therapeutic outcome and therapeutic potential of untested compounds (5-7).

The purpose of this study was to determine the distribution of *Candida* species and *in vitro* susceptibilities of antifungal agents against the *Candida* isolated from the patients referred to a mycology center in southern Iran using E-test for the best management and treatment of those at risk for SC.

MATERIALS AND METHODS

This study was designed in mycology department, Clinical Microbiology Research Center, Shiraz University of Medical Sciences, southern Iran from October 2005 to October 2010. Clinical samples including mouth, blood, abdominal tap, urine, sputum, esophageal, oropharyngeal, vagina, biopsy and broncho alveolar lavage of patients were cultured on sabouraud dextrose agar (Merck, Germany) and incubated at 24°C for 10 days. All *Candida spp.* isolated were cultured on potato dextrose agar (OXOID LTD, Basingstoke, Hampshire, England) twice for 48h at 35°C for the purity inspected. For species typing of the isolates, germ tube and chlamydospore production tests were performed. The carbohydrate assimilation patterns of all the isolates were studied using the API 20 C AUX system according to the manufacturer's procedure (Biomerieux, France). *Candida (C) dubliniensis* sp. was recognized by molecular assay from *Candida albicans* (8) because these species have the same pattern for carbohydrate

assimilation. *Candida parapsilosis* ATCC 22019 and *Candida krusei* ATCC 6258 (9) were quality controls and tested each day for all antifungal agents.

Susceptibility test for the isolates was performed by the agar-based E-test method (Biomerieux, Sweden) with RPMI 1640, 8.4 gram per liter (RPMI; Sigma Chemical Co., St. Louis, Mo.), 2% glucose and 1.5% agar which buffered to PH 7.0 with 0.165 M morpholinepropanesulfonic acid buffer (Sigma, St. Louis, Mo.), poured in 90-mm-diameter plates. The plates were inoculated by dipping a sterile swab into the inoculum suspension adjusted to the turbidity of a 0.5 McFarland standard (10^6 cells/ml) and streaking it across the surface of the agar in four directions. The plates were dried at ambient temperature for 15 minutes before applying the E-test strips. The minimum inhibition concentrations (MIC) endpoints were determined after 24 and 48 h of incubation at 35°C. The MIC was read for amphotericin B, as the drug concentration that zone determined the point of complete inhibition (100%), and for ketoconazole; itraconazole, voriconazole and caspofungin the significant inhibition decreased 80% of the growth. The resistance breakpoints for antifungals are amphotericin B > 1.0; fluconazole ≥ 64 ; itraconazole ≥ 1.0 ; voriconazole ≥ 8.0 ; ketoconazole ≥ 4.0 ; and caspofungin ≥ 2.0 micrograms per milliliter (10-15). MIC50 and MIC90 (the MIC at which 50% and 90% of the isolates are inhibited) were also calculated.

Data were entered into SPSS version 16 and were subsequently analyzed using descriptive statistics and cross tabulation.

RESULTS

Totally, 595 *Candida spp.* were isolated from the

Table 2. Distributions of MIC ($\mu\text{g/ml}$) by E-test method^a.

Species (no. isolates)	Antifungal agent	Range	50%	90%	Number of Resistance (%)
<i>C. albicans</i> (285)	Fluconazole	1.00-64.0	4.000	16.00	30 (10.5%)
	Amphotericin	0.032-1.00	0.032	0.500	20 (7%)
	Ketoconazole	0.002-16.00	0.064	4.00	27 (9.4%)
	Itraconazole	0.016-4.00	0.190	2.00	96 (33.7%)
	Voriconazole	0.025- 0.003-16.00	0.064	4.00	17 (6%)
	Caspofungin	1.00	0.025	0.075	5 (1.8%)
<i>C. krusei</i> (96)	Fluconazole	4.00-64.00	8.00	128.00	64 (66.6%)
	Amphotericin	0.064-1.00	0.125	0.250	3 (3.1%)
	Ketoconazole	0.380-32.00	1.500	4.00	10 (10.4%)
	Itraconazole	0.500-16.00	0.5.00	4.00	83 (86.5%)
	Voriconazole	0.100-32.00	0.500	2.00	19 (19.8%)
	Caspofungin	0.015-0.5	0.24	0.500	4 (4.2%)
<i>C. glabrata</i> (80)	Fluconazole	0.75-256	64.00	128.0	48 (60%)
	Amphotericin	0.013-1	0.190	0.500	2 (2.5%)
	Ketoconazole	0.013-12	1.500	6.00	12 (15%)
	Itraconazole	0.500-16.0	2.00	16.00	68 (85%)
	Voriconazole	0.012-8.00	0.750	3.00	8 (10%)
	Caspofungin	0.03-4.00	0.06	0.12	3 (3.7%)
<i>C. Kefyr</i> (44)	Fluconazole	0.038-128.0	1.00	8.000	20 (45.5%)
	Amphotericin	0.016-1.00	0.190	0.750	2 (4.5%)
	Ketoconazole	0.012-0.190	0.032	0.047	1 (2.3%)
	Itraconazole	0.002-1.00	0.047	0.500	5 (11.4%)
	Voriconazole	0.008-16.00	0.023	0.064	1 (2.3%)
	Caspofungin	0.03-1	0.064	0.125	1 (2.3%)
<i>C. parapsilosis</i> (29)	Fluconazole	2.00-64.00	1.00	4.00	2 (6.9%)
	Amphotericin	0.023-0.500	0.250	0.500	1 (3.5%)
	Ketoconazole	0.016-0.064	0.023	0.047	1 (3.5%)
	Itraconazole	0.023-0.500	0.125	0.250	1 (3.5%)
	Voriconazole	0.006-0.047	0.016	0.032	0.00
	Caspofungin	0.03-2	0.25	1.00	0.00

Resistance is defined as the following MIC in micrograms per milliliter: Flu \geq 64; AMB $>$ 1.0; Keto \geq 4.0; Itra \geq 1.0; Vori \geq 4.0; and Caspofungin \geq 2.0.

patients. The most sites of the isolated (70%) were mouth and lung (sputum and bronchoalveolar lavage), but *Candida* species were also isolated from the blood, cerebro spinal fluid, sinus biopsy, eyes, pleural

and abdominal tap. The most species isolated from the patients was *C. albicans* followed by *C. krusei*, *C. glabrata*, *C. kefyri*, and *C. parapsilosis* (Table 1).

Candida albicans, the most species isolated, was

sensitive to caspofungin, voriconazole, amphotericin B, ketoconazole, and fluconazole with 98.2%, 94%, 93%, 90.6%, and 89.5%, respectively. Of the 96 *C. krusei* strains, 32 (33.4%) were sensitive to fluconazole, 93 (96.9%) to amphotericin B, 86 (89.6%) to ketoconazole, 77 (80.2%) to voriconazole and 92 (95.8%) to caspofungin. Among the 80 *C. glabrata*, the third isolated species, 32 (40%) were found to be sensitive to fluconazole, 78 (97.5%) to amphotericin B, 68 (85%) to ketoconazole, 72 (90%) to voriconazole and 77 (96.3%) to caspofungin. *Candida kefyr* species had the least sensitivity to fluconazole 24 (54.5%), and high sensitivity (> 85%) to the other antifungals. *Candida Parapsilopsis* species showed high sensitivity rate to all antifungal agents. The lowest sensitivity was seen to itraconazole, *C. albicans* 189 (66.3%), *C. glabrata* 12 (15%), and *C. krusei* 13 (13.5%). Table 2 presents the antifungal susceptibility testing of *Candida* isolates to antifungal agents by E-test.

Comparing the MIC₉₀ of species, the lowest MIC₉₀ was observed for caspofungin (0.5 µg/ml). The MIC₉₀ for all *Candida* species were 64 µg/ml for fluconazole, 0.75 µg/ml for amphotericin B, 4 µg/ml for ketoconazole, 4 µg/ml for itraconazole, and 2 µg/ml for voriconazole.

DISCUSSION

In the present study, the agar-based E-test was used and performed well for the testing of antifungal agents as there are reports about the usefulness of this method and agreement between the E-test and the broth micro-dilution MIC for *Candida* species and different types of antifungal agents (16, 17).

In this study, we isolated 595 strains from various clinical samples with higher rate of *C. albicans* (48%), followed by *C. glabrata* (13.5%) and *C. Parapsilosis* (4.8%) (Table 1). The distributions of the species are different in various regions and studies, like 50% *C. albicans*, 24.7% *C. glabrata*, and 1% *C. parapsilosis* in other studies (18, 19). These observations establish the great importance of non-*albicans* *Candida* as a pathogen in clinical samples. It is important that increase in non-*albicans* species in SC with intensive and long-term use of antifungals leads to higher level of resistance of *Candida* strains to the antifungal drugs (20-22). A remarkable point in our study is that the most commonly isolated species was *C. albicans* in the clinical samples followed by *C. krusei* and

C. glabrata which can pose a serious threat due to resistance to the routine antifungal agents.

Amphotericin B deoxycholate was the first systemic antifungal agent for the treatment of invasive fungal infections and has been the drug of choice (23, 24), however, due to nephrotoxicity in up to 80% of the patients, use of amphotericin B has been limited (25). Specific breakpoint for amphotericin B has not been proposed because it can positively affect the immune system and stimulates the body defenses against fungal infections (26, 27); therefore, the correlation between in vitro susceptibility pattern and in vivo responses in patients is not predictable. Resistance to amphotericin B as a routine antifungal agent and valid in our hospital for SC, varies in different studies. All *Candida* isolates in Tseng et al. 2005, were susceptible to amphotericin (17) but in our study 7% of *C. albicans* with MIC₉₀, 0.500 µg/ml, 3.1% of *C. krusei* (MIC₉₀ 0.250 µg/ml), and 2.5% of *C. glabrata* (MIC₉₀ 0.500 µg/ml) were resistant to it.

Development of the triazoles in the 1990s provided alternative options for treating SC. Long-term fluconazole and itraconazole prophylaxis was associated with reduction in susceptibility to these agents. Susceptibility of *C. albicans* to fluconazole in this study was 89.5% (at MIC ≤ 16 µg/mL), comparable with the susceptibility rates reported in other studies (80.9%, 87%, 79% and 87.5%) (17, 28-30). The resistant rate of *C. albicans* to itraconazole in this study was 33.7%, and MIC₉₀ for it was presented ≤ 6 µg/ml. Different rates of resistance to fluconazole and itraconazole were detected in *Candida* strains especially non-*albicans* strain (14, 18). From the standpoint of antifungal resistance, *C. glabrata* and *C. krusei* are clearly the *Candida* species with the greatest potential to acquire resistance to fluconazole and other azoles (14, 15). Of the 96 *C. krusei* strains, 83 (86.3%) were resistant to itraconazole, 64 (66.6%) to fluconazole, 19 (19.8%) to voriconazole, 4 (4.2%) to caspofungin, and 3 (3.1%) to amphotericin B. Also, the MIC of *C. glabrata* was higher than that for all other species of *Candida* to triazoles agents (Table 2).

Blood stream infection due to *C. kefyr* is uncommon, but there has been some reports in immunocompromised patients (31) and resistance to antifungals in the literature (4, 20). In the present study, 7.4% of *Candida* isolates were *C. kefyr*, of which 45.5% were resistant to fluconazole but sensitive to the other antifungals.

There were many species which resisted two or three azole antifungal agents and with higher MIC for other azole antifungal agents. This shows that the resistance to one azole can lead to resistance to other azoles, as reported in other studies (14, 15) and thus, is a caution for use of this agent in clinical practice.

Caspofungin is the first echinocandin, approved in 2002 with the mechanism of inhibiting the 1, 3- β d-glucan as an integral part of the fungal cell wall. In the present study, caspofungin was the most active compound inhibiting 90% of *C. albicans* isolates at 0.075 μ g/ml, *C. krusei* in 0.5 μ g/ml, *C. glabrata* in 0.12 μ g/ml; *C. kefyr* in 0.125 μ g/ml; and *C. parapsilosis* in 1.0 μ g/ml. Some species such as *C. parapsilosis* and *C. guilliermondii* have a relatively higher echinocandin MIC (32).

There are many view points on the use of new antifungal agents. Such agents are very effective but in many countries, especially in the developing ones, they are very expensive or not available to the respective patients. Therefore, we need to know the antifungal susceptibility rates in each region for the available agents in order to better manage the patients.

The successful treatment of SC depends on the early identification of the species and sensitivity patterns to antifungal agents. The high growing rate of non *albicans Candida* resistant to azole confirms the importance of monitoring changes in the distribution of pathogenic *Candida* species. The sensitivity pattern of *Candida* species as revealed in this study shows that amphotericin B, voriconazole, and caspofungin with the lowest MIC seem to be suitable drugs for empirical therapy and fluconazole and itraconazole are not suitable because of their high MIC and *Candida* species resistance to them.

ACKNOWLEDGEMENTS

We would like to thank Dr.M. Moein and M. Didari for their help with culture and drug concentration synthesis and Dr. H. Khajehei for copy editing of the manuscript.

REFERENCES

1. Badiie P, Alborzi A, Joukar M. Molecular assay to detect nosocomial fungal infections in intensive care units. *Europ J Intern Med* 2011; 22: 611-615.
2. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clin Infect Dis* 2002; 34: 730-751.
3. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The hematologic epidemiology of fungal infections in patients with malignancies: the SEIFEM-2004 study. *Haematologia* 2006; 91: 1068-1075.
4. Badiie P, Alborzi A, Shakiba E, Farshad S, Japoni A. Susceptibility of *Candida* species isolated from immunocompromised patients to antifungal agents. *EMHJ* 2011; 17: 425-430.
5. Comert F, Kulah C, Aktas E, Eroglu O, Ozlu N. Identification of *Candida* species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period. *Mycoses* 2007; 50: 52-57.
6. Pfaller MA, Yu WL: Antifungal susceptibility testing. New technology and clinical applications. *Infect Dis Clin North Am* 2001;15: 1227-1261.
7. Eraso E, Ruesga M, Villar-Vidal M, Carrillo-Muñoz AJ, Espinel-Ingroff A, et al. Comparative evaluation of ATB Fungus 2 and Sensititre Yeast One panels for testing in vitro *Candida* antifungal susceptibility. *Rev Iberoam Micol* 2008; 25: 3-6.
8. Mannarelli BM, Kurtzman CP: Rapid identification of *Candida albicans* and other human pathogenic yeast by using short oligonucleotides in a PCR. *J Clin Microbiol* 1998; 36: 1634-1641.
9. Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA: Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant *Candida* spp. *J Clin Microbiol* 2006; 44: 324-326.
10. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ: In vitro susceptibility of *Candida* spp. to caspofungin: four years of global surveillance. *J Clin Microbiol* 2006; 44: 760-763.
11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard; 2nd ed. NCCLS Document M27-A2. Wayne, PA; 2002.
12. Blignaut E, Messer S, Hollis RJ, Pfaller MA. Antifungal susceptibility of south African oral yeast isolates from HIV/AIDS patients and healthy individuals. *Diagn Microbiol Infect Dis* 2002; 44: 169-174.
13. Davey KG, Holmes AD, Johnson EM, Szekeley A, Warnock DW: Comparative evaluation of FUNGITEST and broth microdilution methods for antifungal drug susceptibility testing of *Candida* species and *Cryptococcus neoformans*. *J Clin Microbiol* 1998; 36: 926-930.
14. Swinne D, Wattle M, Van der Flaes M, Nolard N: In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against 132 non-*albicans* bloodstream yeast isolates. *Mycoses* 2004; 47: 177-183.
15. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. *Antimicrob Agents Chemother* 2006; 50: 2009-2015.
16. Pfaller MA, Diekema DJ, Boyken L, Messer SA,

- Tendolkar S, Hollis RJ. Evaluation of the E-test and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of *Candida glabrata* to fluconazole and voriconazole. *J Clin Microbiol* 2003; 41: 1875-1880.
17. Teseng YH, Lee WT, Kuo TC. In-Vitro susceptibility of fluconazole and amphotericin B against *Candida* isolates from women with vaginal candidiasis in Taiwan. *J Food Drug Analysis* 2005; 13: 12-16 .
 18. Mimica LMJ, Ueda SMY, Martino MDV, Navarini A, Martini IJ. *Candida* infection diagnosis: evaluation of *Candida* species identification and characterization of susceptibility profile. *J Bras Patol Med Lab* 2009; 45: 17-23.
 19. Ramani R, Chaturvedi V. Proficiency testing program for clinical laboratories performing antifungal susceptibility testing of pathogenic yeast species. *J Clin Microbiol* 2003; 41: 1143-1146.
 20. Badiee P, Alborzi A, Davarpanah MA, Shakiba E. Distributions and antifungal susceptibility of *Candida* species from mucosal sites in HIV positive patients. *Arch Iran Med* 2010; 13: 282-287.
 21. Berry V, Badyal DK. Sensitivity of clinical isolates of *Candida* species to antifungal drugs. *J Med Education Res* 2006; 8: 214-217.
 22. Badiee P, Alborzi A, Shakiba E, Ziyaeyan M, Rasuli M. Molecular identification and in-vitro susceptibility of *Candida albicans* and *Candida dubliniensis* isolated from Immunocompromised patients. *Iranian Red Cres Med J* 2009; 11: 391-397.
 23. Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EGV, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. *Clin Ther* 2003; 25: 1295-1320.
 24. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen S.H, Amphotericin B. Time for a new "gold standard". *Clin Infect Dis* 2003; 37: 415-425.
 25. Chen SC, Sorrell TC: Antifungal agents. *Med J Aust* 2007; 187: 404-409.
 26. McGuire TR, Trickler WJ, Hock L, Vrana A, Hoie EB, Miller DW. Release of prostaglandin E-2 in bovine brain endothelial cells after exposure to three unique forms of the antifungal drug amphotericin-B: role of COX-2 in amphotericin-B induced fever. *Life Sci* 2003; 72: 2581-2590.
 27. Lord AM, North TE, Zon LI, Prostaglandin E2, making more of your marrow. *Cell Cycle* 2007; 6: 3054-3057.
 28. Saporiti AM, Gómez D, Levalle S, Galeano M, Davel G, Vivot W, et al. Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use. *Rev Argent Microbiol* 2001; 33: 217-222.
 29. Bauters TG, Dhont MA, Temmerman MI, Nelis HJ. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. *Am J Obstet Gynecol* 2002; 187: 569-574.
 30. Citak S, Özçelik B, Cesur S, Abbasoğlu U. In vitro susceptibility of *Candida* isolated from blood culture to some antifungal agents. *Jpn J Infect Dis* 2005; 58: 44-46.
 31. Reuter CW, Morgan MA, Bange FC, Gunzer F, Eder M, Hertenstein B, et al. *Candida kefyr* as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients. *Clin Infect Dis* 2005; 41: 1365-1366.
 32. Bal AM. The echinocandins: three useful choices or three too many? *Int J Antimicrob Agents* 2010; 35: 13-18.

Archive